Innovax-ND-IBD-ILT

Authorised

This medicine is authorised for use in the European Union

avian infectious laryngotracheitis / infectious bursal disease / Marek's disease vaccine (live recombinant) / Newcastle disease virus vaccine (inactivated)

Overview

Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website

Product details

• Name of medicine:
  Innovax-ND-IBD-ILT
• Active substance:
  turkey herpesvirus strain HVT/ND/IBD/ILT (cell-associated), expressing the fusion protein gene of Newcastle disease virus, the VP2 protein gene of infectious bursal disease virus and the glycoproteins gD and gI genes of infectious laryngotracheitis virus, live
• International non-proprietary name (INN) or common name:
  • avian infectious laryngotracheitis
  • infectious bursal disease
  • Marek's disease vaccine (live recombinant)
  • Newcastle disease virus vaccine (inactivated)

Pharmacotherapeutic group

• Immunologicals for aves
• Domestic fowl
• Live viral vaccines

Authorisation details

• EMA product number:
  EMEA/V/C/006442

Assessment history

Initial marketing authorisation documents

CVMP summary of positive opinion for Innovax-ND-IBD-ILT

Adopted Reference Number: EMA/155368/2025